IRIS
CENCINI, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.374
EU - Europa 2.881
AS - Asia 1.583
SA - Sud America 308
AF - Africa 91
OC - Oceania 4
Totale 8.241
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.333
RU - Federazione Russa 732
GB - Regno Unito 669
CN - Cina 512
SG - Singapore 494
IE - Irlanda 374
IT - Italia 295
BR - Brasile 260
SE - Svezia 200
VN - Vietnam 188
FR - Francia 142
UA - Ucraina 128
HK - Hong Kong 122
DE - Germania 114
FI - Finlandia 105
KR - Corea 54
IN - India 51
ZA - Sudafrica 40
TR - Turchia 32
AR - Argentina 24
BD - Bangladesh 21
JP - Giappone 21
PL - Polonia 21
CA - Canada 19
IQ - Iraq 19
NL - Olanda 17
AT - Austria 16
MX - Messico 15
BE - Belgio 14
KE - Kenya 14
CZ - Repubblica Ceca 12
NG - Nigeria 11
SA - Arabia Saudita 11
ES - Italia 10
PK - Pakistan 8
CI - Costa d'Avorio 7
IR - Iran 7
EC - Ecuador 6
MA - Marocco 6
SK - Slovacchia (Repubblica Slovacca) 6
UZ - Uzbekistan 6
CO - Colombia 5
EG - Egitto 5
PH - Filippine 5
TN - Tunisia 5
AU - Australia 4
ID - Indonesia 4
LT - Lituania 4
NP - Nepal 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
CL - Cile 3
JO - Giordania 3
OM - Oman 3
PE - Perù 3
PY - Paraguay 3
BG - Bulgaria 2
BO - Bolivia 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GR - Grecia 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
NO - Norvegia 2
PA - Panama 2
QA - Qatar 2
AL - Albania 1
AM - Armenia 1
BY - Bielorussia 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
HN - Honduras 1
IM - Isola di Man 1
JM - Giamaica 1
KZ - Kazakistan 1
LV - Lettonia 1
MK - Macedonia 1
MT - Malta 1
MY - Malesia 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
VE - Venezuela 1
Totale 8.241
Salva come PNG Salva come JPEG
Città #
Southend 594
Fairfield 389
Dublin 372
Dallas 336
Singapore 312
Ashburn 275
Moscow 216
Santa Clara 184
Chandler 170
Woodbridge 170
Houston 148
Beijing 147
Seattle 139
Ann Arbor 135
Wilmington 129
Cambridge 120
Hong Kong 118
Jacksonville 106
San Jose 101
Hefei 97
Siena 77
Princeton 63
Dearborn 60
The Dalles 60
Seoul 54
Ho Chi Minh City 50
Los Angeles 50
Hanoi 48
Lauterbourg 47
Nanjing 44
Munich 42
Johannesburg 37
Helsinki 35
New York 33
Council Bluffs 32
Turku 32
Milan 29
Izmir 28
Lappeenranta 27
Menlo Park 25
Florence 23
Boardman 22
San Mateo 22
São Paulo 22
Orem 20
Redondo Beach 18
Dong Ket 16
Buffalo 15
Brussels 14
Chennai 13
London 13
Bengaluru 12
Chicago 11
Frankfurt am Main 11
Nanchang 11
San Diego 11
Tianjin 11
Warsaw 11
Guangzhou 10
Haiphong 10
Jinan 10
Rome 10
San Francisco 10
Shanghai 10
Atlanta 9
Bologna 9
Columbus 9
Da Nang 9
Denver 9
Nairobi 9
Rio de Janeiro 9
Shenyang 9
Tokyo 9
Abuja 8
Baghdad 8
Belo Horizonte 8
Kunming 8
Montreal 8
Vienna 8
Abidjan 7
Brooklyn 7
Changsha 7
Portsmouth 7
Stockholm 7
Toronto 7
Brno 6
Hebei 6
Jiaxing 6
Poplar 6
Amsterdam 5
Boston 5
Maceió 5
New Delhi 5
Nuremberg 5
Phoenix 5
Tashkent 5
Cagliari 4
Dhaka 4
Fortaleza 4
Fuzhou 4
Totale 5.713
Salva come PNG Salva come JPEG
Nome #
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients 430
IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications 287
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 273
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 248
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma 235
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 232
Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large B-cell lymphoma 228
Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma 218
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab 217
New perspectives for patients with primary CNS lymphoma 214
Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment 214
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopenia 213
Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma 211
Atypical clinical presentation of visceral leishmaniasis in a patient with non-Hodgkin lymphoma 209
Impressive and durable response in a case of multiple relapsed mantle cell lymphoma treated with bortezomib and rituximab 209
Primary Nasopharyngeal Hodgkin Lymphoma 203
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 195
Hodgkin lymphoma in the elderly: new perspectives and a 10-year monocenter real-life experience 192
Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma 189
Long term remission in a case of Plasmablastic lymphoma treated with COMP (Cyclophosphamide, Liposomal Doxorubicin, Vincristine, Prednisone) and Bortezomib 184
Prognostic impact of tumor-associated macrophages, lymphocyte-to-monocyte and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma 182
Treatment decisions and outcome in very elderly patients with diffuse large B-Cell lymphoma 178
Therapeutic use of Brentuximab Vedotin In Cd30+ hematologic malignancies 177
Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review 176
Radiotherapy with rituximab as first-line treatment for early-stage follicular lymphoma 173
Prognostic role of m2 Tumour-Associated macrophages in lymphoproliferative disorders 173
Coexistence of Serum Monoclonal Gammopathy of Uncertain Significance and Hodgkin Lymphoma 173
Correction to: IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications (Virchows Archiv, (2020), 477, 1, (143-150), 10.1007/s00428-019-02712-8) 167
Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma 149
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 146
How to manage early-stage follicular lymphoma 139
Characteristics of primary cutaneous lymphoma in Italy: a tertiary care, single-center study 138
Non-Invasive Imaging Including Line-Field Confocal Optical Coherence Tomography (LC-OCT) for Diagnosis of Cutaneous Lymphomas 137
Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series 130
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study 129
Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications 127
Are small lymphocytic lymphoma and chronic lymphocytic leukemia the same disease? The unsolved dilemma 126
Is bendamustine plus rituximab a suitable option for rituximab-refractory duodenal-type follicular lymphoma? 126
Two secondary localisation of non-Hodgkin's lymphomas in the upper gastrointestinal tract 120
Survival outcomes of patients with mantle cell lymphoma: a retrospective, 15-Year, real-life study 104
Immunodeficiency-related high-grade B-cell lymphoma with 11q aberration: Further evidence for a lymphoma entity from a patient with simultaneous papillary renal cell carcinoma following pediatric kidney transplant 101
Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies 97
Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the “RTL” (regional Tuscan lymphoma network) 97
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi 97
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 96
Development and implementation of the International AIDA Network Castleman’s disease registry 85
Tp53 disruptions: Is there a marker of poor prognosis in chronic lymphoproliferative disorders? 82
The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi 73
Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone 64
Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the “RTL” (Regional Tuscan Lymphoma network) 58
Totale 8.421
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.257
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.257
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021208 0 0 0 0 0 0 0 0 0 82 64 62
2021/2022476 29 47 34 47 31 27 15 15 24 48 54 105
2022/2023636 34 62 85 73 77 130 17 43 63 6 24 22
2023/2024578 20 15 35 58 14 125 220 10 8 32 3 38
2024/20251.278 45 71 169 50 157 73 20 65 59 85 155 329
2025/20262.809 242 384 291 446 680 128 331 90 91 126 0 0
Totale 8.421